Introduction Despite increasing evidence of its efficacy in advanced age or in mild or severe
strokes, intravenous thrombolysis remains underused for acute ischaemic stroke (AIS). Our …

Background Thrombolysis remains the only approved therapy for acute ischaemic stroke
(AIS); however, its utilisation is reported to be low. Aims This study aimed to determine the …

Thrombolysis has been shown to be an effective treatment for ischaemic stroke. The major
obstacles to more widespread use of this therapy are lack of awareness that treatment is …

Background Only 2%-3% of patients with acute ischemic stroke receive thrombolysis. The
aim of this study was to identify the reasons for exclusion from thrombolysis in patients …

Background: Several contraindications for intravenous thrombolysis are not based on
controlled trials. Specialized stroke centers often apply less restrictive criteria. The aim of our …

What is known and Objective: Thrombolysis is currently the only evidence‐based
pharmacological treatment available for acute ischaemic stroke (AIS); however, its current …

Objectives: To determine the eligibility of patients with ischaemic stroke admitted to the 2nd
Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland, for …

Objective The objective of the present study is to independently and systematically assess
the harms and benefits of intravenous thrombolysis for patients with presumed acute …

Background and purpose: barriers within the patient pathway can prevent early
administration of thrombolytic therapy in patients admitted with acute stroke. This systematic …

Abstract According to current European Alteplase license, therapeutic-window for
intravenous (IV) thrombolysis in acute ischemic stroke has recently been extended to 4.5 h …